Corticosteroid Suppression of VEGF-A in Infantile Hemangioma-Derived Stem Cells
- 18 March 2010
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 362 (11), 1005-1013
- https://doi.org/10.1056/nejmoa0903036
Abstract
Corticosteroids are commonly used to treat infantile hemangioma, but the mechanism of action of this therapy is unknown. We investigated the effect of corticosteroids in a previously described in vivo model of infantile hemangioma and in cultured hemangioma-derived cells. We tested hemangioma-derived stem cells for vasculogenic activity in vivo after implantation into immune-deficient (nude) mice. We studied dexamethasone treatment of both the cells before implantation and the mice after implantation. We also tested hemangioma-derived stem cells for expression of vascular endothelial growth factor A (VEGF-A) in vitro and studied the inhibition of VEGF-A expression, using short hairpin RNA (shRNA) in vivo and in vitro. Systemic treatment with dexamethasone led to dose-dependent inhibition of tumor vasculogenesis in the murine model. Pretreatment of hemangioma-derived stem cells in vitro before implantation also inhibited vasculogenesis. Dexamethasone suppressed VEGF-A production by hemangioma-derived stem cells in vitro but not by hemangioma-derived endothelial cells or human umbilical-vein endothelial cells. Silencing VEGF-A in hemangioma-derived stem cells reduced vasculogenesis in vivo. VEGF-A was detected in hemangioma specimens in the proliferating phase but not in the involuting phase and was shown by immunostaining to reside outside of vessels. Corticosteroid treatment suppressed other proangiogenic factors in hemangioma-derived stem cells, including urokinase plasminogen activator receptor, interleukin-6, monocyte chemoattractant protein 1, and matrix metalloproteinase 1. In a murine model, dexamethasone inhibited the vasculogenic potential of stem cells derived from human infantile hemangioma. The corticosteroid also inhibited the expression of VEGF-A by hemangioma-derived stem cells, and silencing of VEGF-A expression in these cells inhibited vasculogenesis in vivo.Keywords
This publication has 35 references indexed in Scilit:
- Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancerBritish Journal of Cancer, 2008
- Infantile Hemangiomas: An Emerging Health Issue Linked to an Increased Rate of Low Birth Weight InfantsThe Journal of Pediatrics, 2008
- Vascular endothelial growth factor expression by hyalocytes and its regulation by glucocorticoidBritish Journal of Ophthalmology, 2008
- Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangiomaNature Medicine, 2008
- Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient miceJCI Insight, 2008
- Hypoxia-Induced Mediators of Stem/Progenitor Cell Trafficking Are Increased in Children With HemangiomaArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Colon Cancer Cell–Derived Tumor Necrosis Factor-α Mediates the Tumor Growth–Promoting Response in Macrophages by Up-regulating the Colony-Stimulating Factor-1 PathwayCancer Research, 2007
- Endothelial progenitor cells from infantile hemangioma and umbilical cord blood display unique cellular responses to endostatinBlood, 2006
- Increased Tie2 Expression, Enhanced Response to Angiopoietin-1, and Dysregulated Angiopoietin-2 Expression in Hemangioma-Derived Endothelial CellsThe American Journal of Pathology, 2001
- The Treatment of HemangiomasAnnals of Surgery, 1976